Biomarkers in Alzheimer's disease: Emerging trends and clinical implications

Affiliations

¹ Department of Neurology and National Center for Neurological Disorders, Huashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai Medical College, Fudan University, Shanghai 200040, China.

Piaopiao Lian et al. Chin Med J (Engl). 2025.

. 2025 May 5;138(9):1009-1012.

doi: 10.1097/CM9.0000000000003579. Epub 2025 Apr 1.

¹ Department of Neurology and National Center for Neurological Disorders, Huashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai Medical College, Fudan University, Shanghai 200040, China.

No abstract available

Conflict of interest statement

None.

1. Chen YG. Research progress in the pathogenesis of Alzheimer’s disease. Chin Med J 2018;131:1618–1624. doi: 10.4103/0366-6999.235112. - PMC - PubMed
1. van Dyck CH Swanson CJ Aisen P Bateman RJ Chen C Gee M, et al. . Lecanemab in early Alzheimer’s disease. N Engl J Med 2023;388:9–21. doi: 10.1056/NEJMoa2212948. - PubMed
1. Ossenkoppele R Smith R Mattsson-Carlgren N Groot C Leuzy A Strandberg O, et al. . Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease: A head-to-head comparison against amyloid positron emission tomography and magnetic resonance imaging. JAMA Neurol 2021;78;961–971. doi: 10.1001/jamaneurol.2021.1858. - PMC - PubMed
1. Kato T, Inui Y, Nakamura A, Ito K. Brain fluorodeoxyglucose (FDG) PET in dementia. Ageing Res Rev 2016;30:73–84. doi: 10.1016/j.arr.2016.02.003. - PubMed
1. Frisoni GB Bocchetta M Chételat G Rabinovici GD de Leon MJ Kaye J, et al. . Imaging markers for Alzheimer disease: which vs how. Neurology 2013;81:487–500. doi: 10.1212/WNL.0b013e31829d86e8. - PMC - PubMed